Document is current
Any future updates will be listed below
-
Authors
Blumenfeld, Andrew M.
Stark, Richard J.
Freeman, Marshall C.
Orejudos, Amelia
Manack Adams, Aubrey
-
Funding
Funding for this research was provided by:
Allergan plc
- License Information
-
More Information
Article History
Received: 13 October 2017
Accepted: 19 January 2018
First Online: 5 February 2018
Ethics approval and consent to participate
: The study received ethical approval from the Institutional Review Board or Independent Ethics Committee at each site, and written informed consent was obtained from patients before study enrollment.
: Not applicable.
: Andrew M. Blumenfeld has served on advisory boards and/or has consulted for Allergan, Pernix, Teva, Avanir, Depomed, and Supernus, and has received funding for travel, speaking, and/or royalty payments from Allergan. Richard J. Stark has served on advisory boards and/or has consulted for Allergan, has served on advisory boards for Novartis and has received funding for travel and/or speaking payments from Allergan, MSD, AbbVie and SciGen, and from In Vivo Academy relating to a Pfizer-sponsored project. Marshall C. Freeman has served on advisory boards and/or has consulted or received research support from Alder, Allergan, Avani, Dr. Reddy’s Laboratories, Eli Lilly, Scion, and Teva. Amelia Orejudos is an employee of Allergan plc. Aubrey Manack Adams is an employee of Allergan plc and owns stock in the company.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
